You are here: Home » International » News » Others
Business Standard

New Covid-19 strain enters China after UK returnee tests positive

Beijing grants conditional nod to homegrown vaccine

Coronavirus | Coronavirus Vaccine | Coronavirus Tests


The Sydney Opera House fireworks soared into the sky, but the harbour below was empty as a ghost town, a fittingly creepy send-off for a year that will not be missed. Photo: PTI
The Sydney Opera House fireworks soared into the sky, but the harbour below was empty as a ghost town, a fittingly creepy send-off for a year that will not be missed. Photo: PTI

China has detected its first imported case of the new variant that is spreading rapidly around Britain, according to a publication run by the Chinese Center for Disease Control and Prevention (CDC). The variant was detected in a 23-year-old female student returning to China from Britain, who was tested in Shanghai on December 14, according to the latest edition of China CDC Weekly. The case “poses a great potential threat to the prevention and control of Covid-19 in China”, the publication said. Vaccine for general population Meanwhile, the drug regulator approved the country’s first vaccine for general public use, a sign of confidence in the experimental shots the nation plans to roll out within and beyond its borders. China’s National Medical Products Administration gave the authorisation to a Covid-19 vaccine developed by state-owned China National Biotec Group, a unit of Sinopharm, officials told reporters in Beijing Thursday. With the approval, the vaccine — which has been authorised for emergency use in China since mid-year along with other frontrunner shots — will be made commercially available, meaning it can be administered to the general population. Regulators from the US to Singapore have approved shots over the past month, among them vaccines developed by Pfizer, Moderna and AstraZeneca, but those have been largely for emergency use, a status China granted to its developers months ago. China will target members of the population at higher risk in its inoculations, among them the elderly and those with pre-existing conditions, and then roll vaccines out to the general public, Zeng Yixin, vice minister of the country’s National Health Commission, said at the briefing. The country has already administered more than 4.5 million doses of Covid-19 vaccine, with 3 million alone given since mid-December, Zeng said. It is said to be aiming to inoculate 50 million people against the virus by early February, ahead of the annual Lunar New Year holiday. The ratio of adverse reactions, including allergies, is about two in every 1 million, Zeng said Thursday. Vaccine for Pakistan Pakistan has decided to pre-book 1.1 million doses of Covid-19 vaccine developed by the Chinese state-owned company Sinopharm, the health ministry said here on Thursday, as the number of cases reached 479,715 after 2,475 new infections were detected in the country. China on Thursday granted conditional approval to the country’s first homegrown Covid-19 vaccine developed by Sinopharm.

The approval came a day after Sinopharm said its vaccine showed 79.34 per cent efficacy and a 99.52 per cent antibody-positive conversion rate in the interim results of Phase III clinical trials. The decision to procure the vaccine was made in the meeting of a special cabinet committee on Wednesday after Sinopharm said that its vaccine was 79.34 per cent effective, the Ministry of National Health Services said. The Drug Regulatory Authority of Pakistan (Drap) has not yet approved the emergency use of the drug which once approved would be given free to all frontline health workers in the first quarter of 2021.

Global deaths cross 1.8-million mark Global deaths from Covid-19 has passed 1.8 million even as Tokyo recorded a record number of new infections, and Japan warned it could consider a state of emergency if the new outbreak can’t be contained. Governments across the globe asked their citizens to celebrate the New Year at home. Cities that had gone weeks without new infections, including Beijing and Melbourne, are now reporting clusters, and the new, highly transmissible virus strain was found in Singapore and California. The variant is more transmissible and appears to affect a higher proportion of people under 20, according to a report. Bloomberg Moderna shows 94.1% efficacy in UK trial: Study Results from the primary analysis of the ongoing phase 3 clinical trial of US biotechnology company Moderna's Covid-19 vaccine have revealed 94.1 per cent efficacy of the therapeutic in preventing symptomatic infections and severe illness, according to a peer-reviewed study. The study, published on Wednesday in The New England Journal of Medicine, found that among over 30,000 participants randomised to receive the vaccine or a placebo, 11 in the vaccine group developed symptomatic Covid-19 compared to 185 participants who received the placebo. PTI Putin battles to sell Russia’s vaccine in rift with the West Russia is accusing the West of maligning its achievements in the global race to defeat Covid-19 as its attempts to win key markets for its Sputnik V vaccine run up against the demands of regulators. “We understand the game,” Kirill Dmitriev, chief executive officer of the Russian Direct Investment Fund, which backed Sputnik V’s development and negotiates its roll-out, said in an interview. “It’s a combination of some misunderstanding, some strong bias and, really, some very strong efforts to under­mine the Russian vaccine.” Bloomberg

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 01 2021. 01:51 IST